A successful example of applying the synthetic lethality approach is the targeting of cancers with dysfunction of the breast-cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) by poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors [49]. This evidence concerns the gene BRCA1 and medical procedure.